Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Sell
38
ADXN Quote, Financials, Valuation and Earnings
Last price:
$7.50
Seasonality move
:
38.09%
Day range:
$7.81 - $8.65
52-week range:
$5.60 - $27.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
14.43x
P/B ratio:
0.63x
Volume:
21.8K
Avg. volume:
44.3K
1-year change:
41.74%
Market cap:
$8.3M
Revenue:
$1.8M
EPS (TTM):
-$0.34
Analysts' Opinion
-
Consensus RatingAddex Therapeutics has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Addex Therapeutics has an estimated upside of 284.12% from its current price of $7.81.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $7.81.
Fair Value
-
According to the consensus of 0 analysts, Addex Therapeutics has 284.12% upside to fair value with a price target of -- per share.
ADXN vs. S&P 500
-
Over the past 5 trading days, Addex Therapeutics has overperformed the S&P 500 by 0.68% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Addex Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Addex Therapeutics revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Addex Therapeutics reported revenues of $62.3K.
Earnings Growth
-
Addex Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Addex Therapeutics reported earnings per share of -$2.78.
Enterprise value:
4.4M
EV / Invested capital:
0.33x
Price / LTM sales:
14.43x
EV / EBIT:
--
EV / Revenue:
6.92x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.65x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
62.62%
Net Income Margin (TTM):
-838.93%
Return On Equity:
91.08%
Return On Invested Capital:
91.08%
Operating Margin:
-1155.7%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1.3M | $2.2M | $630K | $371.1K | $62.3K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$22.5M | -$5.3M | -$12.5M | -$848.4K | -$719.5K | |
| EBITDA | -$22.4M | -$5.2M | -$13.7M | -$718.8K | -$1.7M | |
| Diluted EPS | -$71.22 | -$19.59 | -$0.34 | -$4.08 | -$2.78 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $20.9M | $18.7M | $12M | $6.3M | $4.8M | |
| Total Assets | $21.4M | $19.3M | $12.6M | $6.7M | $14.5M | |
| Current Liabilities | $2.4M | $3.5M | $4.2M | $2.1M | $1.1M | |
| Total Liabilities | $4.2M | $5.1M | $4.4M | $2.4M | $1.3M | |
| Total Equity | $17.1M | $14.3M | $8.2M | $4.3M | $13.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$17.1M | -$11.7M | -$6.7M | -$2.7M | -$711.8K | |
| Cash From Investing | -$23.6K | -$6.4K | $5.4M | -$870 | $229.7K | |
| Cash From Financing | $12.4M | $5.9M | -$41K | -$105.2K | $4.9K | |
| Free Cash Flow | -$17.1M | -$11.7M | -$6.7M | -$2.7M | -$713.3K | |
ADXN
Sector
Market Cap
$8.3M
$46.5M
Price % of 52-Week High
27.99%
47.23%
Dividend Yield
0%
0%
Shareholder Yield
-12.49%
-0.6%
1-Year Price Total Return
41.74%
-31.38%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$7.81
200-day SMA
Sell
Level
$10.20
Bollinger Bands (100)
Sell
Level
7.91 - 10.57
Chaikin Money Flow
Sell
Level
-38.8M
20-day SMA
Sell
Level
$7.93
Relative Strength Index (RSI14)
Sell
Level
44.89
ADX Line
Buy
Level
20.53
Williams %R
Neutral
Level
-67.7419
50-day SMA
Sell
Level
$9.03
MACD (12, 26)
Sell
Level
-0.28
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Neutral
Level
198.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-114.1267)
Sell
CA Score
(Annual)
Level (-7.8636)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (13.2722)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
Stock Forecast FAQ
In the current month, ADXN has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ADXN average analyst price target in the past 3 months is --.
-
Where Will Addex Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Addex Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Addex Therapeutics?
Analysts are divided on their view about Addex Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Addex Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Addex Therapeutics's Price Target?
The price target for Addex Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ADXN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Addex Therapeutics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ADXN?
You can purchase shares of Addex Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Addex Therapeutics shares.
-
What Is The Addex Therapeutics Share Price Today?
Addex Therapeutics was last trading at $7.50 per share. This represents the most recent stock quote for Addex Therapeutics. Yesterday, Addex Therapeutics closed at $7.81 per share.
-
How To Buy Addex Therapeutics Stock Online?
In order to purchase Addex Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is down 5.5% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 5.98% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is down 4.77% over the past day.
